| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7e8d2afa63dbd8bbb90545722d3f54c1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6bfa7ae087aaa697945cfe6ef81e0082 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-02 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-7051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-545
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0638
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| filingDate |
2020-07-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6931886ac6f28bc576602c28af6c7e19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_53765a7f1b807955e88240f0673a2ef9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d322279282dd4eecc5ed645357a6571
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_28304ab1997cec362303d7b6474df8d5 |
| publicationDate |
2021-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021006316-A1 |
| titleOfInvention |
Specific marker for identifying t cells specifically attacking cancer cells |
| abstract |
The present disclosure provides a specific marker for identifying T cells specifically attacking cancer cells and the utilization of the marker. According to the present disclosure, a marker that has a high specificity for identifying T cells specifically attacking cancer cells is provided. According to the present disclosure, treatment or prevention of cancer in a subject with the use of a cell subpopulation contained in a tumor tissue infiltrating CD106+ T cell population or cells expressing a T cell receptor (TCR) expressed thereby can be provided. According to another embodiment of the present disclosure, a method for producing a cell pharmaceutical can be provided. According to the present disclosure, further, a method that comprises using the amount of a cell subpopulation as an index of the responsiveness of a subject to a cancer immunotherapy can be provided. According to the present disclosure, furthermore, a method for acquiring a tumor specific TCR sequence can be provided. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022145490-A1 |
| priorityDate |
2019-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |